文章：

胶质母细胞瘤标准治疗方案：对肿瘤演化的影响及临床前模型中的反向转化研究

Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models

原文发布日期：24 July 2024

DOI: 10.3390/cancers16152638

类型: Article

开放获取: 是

英文摘要：

Glioblastoma (GBM) presents a significant public health challenge as the deadliest and most common malignant brain tumor in adults. Despite standard-of-care treatment, which includes surgery, radiation, and chemotherapy, mortality rates are high, underscoring the critical need for advancing GBM therapy. Over the past two decades, numerous clinical trials have been performed, yet only a small fraction demonstrated a benefit, raising concerns about the predictability of current preclinical models. Traditionally, preclinical studies utilize treatment-naïve tumors, failing to model the clinical scenario where patients undergo standard-of-care treatment prior to recurrence. Recurrent GBM generally exhibits distinct molecular alterations influenced by treatment selection pressures. In this review, we discuss the impact of treatment—surgery, radiation, and chemotherapy—on GBM. We also provide a summary of treatments used in preclinical models, advocating for their integration to enhance the translation of novel strategies to improve therapeutic outcomes in GBM.

摘要翻译： 

胶质母细胞瘤（GBM）作为成人中最致命且最常见的恶性脑肿瘤，构成了重大的公共卫生挑战。尽管采用包括手术、放疗和化疗在内的标准治疗方案，其死亡率仍然居高不下，这凸显了推进GBM治疗的迫切需求。过去二十年间，大量临床试验得以开展，但仅有少数显示出疗效，引发了人们对当前临床前模型预测能力的担忧。传统上，临床前研究使用未经治疗的肿瘤模型，未能模拟患者在复发前已接受标准治疗的临床实际情况。复发性GBM通常表现出受治疗选择压力影响的独特分子改变。本文综述了手术、放疗和化疗等治疗手段对GBM的影响，总结了临床前模型中使用的治疗方法，并主张整合这些方法以促进新策略的转化，从而改善GBM的治疗效果。

原文链接：

Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models